Rising prevalence of cardiovascular disorders, increasing geriatric population base coupled and growing need for repeat revascularization procedure are the major growth propellers of coronary artery bypass graft devices (CABG) market. Increasing incidences of coronary heart diseases resulting due to unhealthy lifestyle is another high impact rendering driver for this market. The introduction of minimally invasive devices (minimally invasive direct coronary artery bypass, MIDCAB), anastomosis assist devices (AAD), and endoscopic vessel harvesting (EVH) devices are also impacting the market growth positively. MIDCABs are being very popular recently due to the benefits of reduced risk of infection, less recovery time, less bleeding, and a smaller incision.
Based on the number of coronary arteries used in the bypass surgery, the market is segmented into single, double, triple, and quadruple CABG surgery. This depends on the number of stenoses the patient is suffering from. On the basis of the techniques used, this market is segmented into on-pump CABG (ONCAB) and off-pump CABG (OPCAB). An ONCAB procedure needs cardiopulmonary bypass or heart-lung machine, whereas OPCAB procedures are held in the absence of heart-lung machines. OPCAB is a relatively newer technology and is expected to be the fastest growing segment in the next six years.
Coronary artery bypass graft devices market is globally divided into North America, Europe, and Asia Pacific and RoW. North America and Europe market for CABG is matured one with all the versions of minimally invasive CABG surgeries available and is expected to have the largest share during the forecast period. In Europe, this market is expected to gain volumes due to rising numbers of coronary diseases. Due to the increase in medical tourism industry and growth in per capita income in Asian countries, the Asia-Pacific market is expected to flourish in the forecast period. China is expected to be the fastest growing market for these devices attributed to the growing access of the public with healthcare professional and expanding economy.
The major players in coronary artery bypass graft devices market are Heratport, Medtronic, Guidant, Terumo, Maquet, Sorin Group, St. Jude Medicals, Edward Life sciences, Heartwave, Boston Scientific, Thoratec, Articure, Teleflex Medicals, and Biosense Webster. ONCAB, OPCAB, AAD, and EVH are majorly marketed by Maquet.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.
"The quality of research they have done for us has been excellent..."
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for Covid19 as a key market contributor.